SG11201501870RA - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer - Google Patents

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Info

Publication number
SG11201501870RA
SG11201501870RA SG11201501870RA SG11201501870RA SG11201501870RA SG 11201501870R A SG11201501870R A SG 11201501870RA SG 11201501870R A SG11201501870R A SG 11201501870RA SG 11201501870R A SG11201501870R A SG 11201501870RA SG 11201501870R A SG11201501870R A SG 11201501870RA
Authority
SG
Singapore
Prior art keywords
androgens
treatment
prostate cancer
resistant prostate
metastatic castrate
Prior art date
Application number
SG11201501870RA
Other languages
English (en)
Inventor
Isan Chen
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49293921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201501870R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of SG11201501870RA publication Critical patent/SG11201501870RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
SG11201501870RA 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer SG11201501870RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705900P 2012-09-26 2012-09-26
PCT/US2013/061197 WO2014052237A1 (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Publications (1)

Publication Number Publication Date
SG11201501870RA true SG11201501870RA (en) 2015-04-29

Family

ID=49293921

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201501870RA SG11201501870RA (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG10201902568YA SG10201902568YA (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG10201912719TA SG10201912719TA (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201902568YA SG10201902568YA (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG10201912719TA SG10201912719TA (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Country Status (35)

Country Link
US (7) US9884054B2 (zh)
EP (3) EP2900224A1 (zh)
JP (4) JP6351597B2 (zh)
KR (3) KR102210825B1 (zh)
CN (4) CN109999036A (zh)
AU (4) AU2013323861C1 (zh)
BR (1) BR112015006705A8 (zh)
CA (1) CA2885415C (zh)
CL (1) CL2015000715A1 (zh)
CR (1) CR20150140A (zh)
CY (1) CY1123716T1 (zh)
DK (1) DK3305285T3 (zh)
EA (3) EA202190820A1 (zh)
EC (1) ECSP15011764A (zh)
ES (1) ES2836424T3 (zh)
GT (1) GT201500071A (zh)
HK (2) HK1252867A1 (zh)
HR (1) HRP20201721T1 (zh)
HU (1) HUE051211T2 (zh)
IL (3) IL237692B2 (zh)
IN (1) IN2015DN02387A (zh)
LT (1) LT3305285T (zh)
MX (2) MX371020B (zh)
MY (1) MY180834A (zh)
NI (1) NI201500042A (zh)
NZ (3) NZ744456A (zh)
PE (1) PE20150765A1 (zh)
PH (3) PH12015500615B1 (zh)
PT (1) PT3305285T (zh)
RS (1) RS60976B1 (zh)
SG (3) SG11201501870RA (zh)
SI (1) SI3305285T1 (zh)
UA (2) UA117663C2 (zh)
WO (1) WO2014052237A1 (zh)
ZA (1) ZA201808499B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037389T2 (hu) 2010-02-16 2018-08-28 Aragon Pharmaceuticals Inc Androgén receptor modulátorok és alkalmazásaik
WO2013090921A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
EA202190820A1 (ru) 2012-09-26 2021-10-29 Арагон Фармасьютикалз, Инк. Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
MX2017007206A (es) 2014-12-05 2018-01-30 Aragon Pharmaceuticals Inc Composiciones anticancerigenas.
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
DK3226842T3 (da) * 2014-12-05 2021-01-25 Aragon Pharmaceuticals Inc Anticancersammensætninger
KR101718226B1 (ko) 2015-08-05 2017-03-20 울산대학교 산학협력단 사쿠라소사포닌 화합물을 유효성분으로 포함하는 안드로겐 수용체 관련 질환의 예방 또는 치료용 조성물
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER
BR112021014969A2 (pt) * 2019-01-30 2021-10-05 Aragon Pharmaceuticals, Inc. Antiandrogênios para o tratamento de câncer de próstata metastático sensível à castração
EP4054572A1 (en) * 2019-11-04 2022-09-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE550650A (zh) 1955-08-30
JPS4916937B1 (zh) 1970-01-21 1974-04-25
US3823240A (en) 1970-10-06 1974-07-09 Rhone Poulenc Sa Fungicidal hydantoin derivatives
GB1472467A (en) 1974-04-19 1977-05-04 Wyeth John & Brother Ltd Thiohydantoins
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE2614831A1 (de) 1976-04-06 1977-10-20 Bayer Ag 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
MC1220A1 (fr) 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
CA1138334A (en) 1977-10-28 1982-12-28 Karl Bernauer Pharmaceutical preparations containing certain urea derivatives
ZA786739B (en) 1977-12-01 1980-07-30 Wellcome Found Hydantoin derivatives and salts thereof,their syntheses,and intermediates,and pharmaceutical formulations
EP0004723A1 (en) 1978-03-30 1979-10-17 Beecham Group Plc Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them
FR2449448B1 (fr) 1979-02-20 1983-05-27 Inst Nat Radio Elements Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation
FI801184A (fi) 1979-04-24 1980-10-25 Hoffmann La Roche Foerfarande foer framstaellning av imidazolidinderivat
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS57197268A (en) 1981-05-29 1982-12-03 Sumitomo Chem Co Ltd Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient
EP0091596B1 (de) 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
US4473393A (en) 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
JPS59210083A (ja) 1983-05-13 1984-11-28 Otsuka Chem Co Ltd １，３，４−チアジアゾ−ル−５−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS6092285A (ja) 1983-10-26 1985-05-23 Shionogi & Co Ltd イソオキサゾ−ル系環状尿素類
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS60239737A (ja) 1984-05-14 1985-11-28 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
JPH0219363Y2 (zh) 1985-07-31 1990-05-29
EP0230654B1 (en) 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
DE3604042A1 (de) 1986-02-08 1987-08-13 Hoechst Ag Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
JPS649978A (en) 1987-07-02 1989-01-13 Shionogi & Co Perfluoroalkylisoxazole derivative
US4859228A (en) 1987-07-16 1989-08-22 Ici Americas Inc Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
FR2619381B1 (fr) 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
CA1331757C (en) 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5614620A (en) 1988-03-30 1997-03-25 Arch Development Corporation DNA binding proteins including androgen receptor
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US6307030B1 (en) 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE3835168A1 (de) 1988-10-15 1990-04-19 Bayer Ag N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
FR2656302B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
JP2845384B2 (ja) 1991-11-14 1999-01-13 キヤノン株式会社 画像処理装置
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5346913A (en) 1992-05-26 1994-09-13 Rohm And Haas Company N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
DE4316542C1 (de) 1993-05-18 1994-07-21 Schaefer Micomed Gmbh Osteosynthesevorrichtung
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2715402B1 (fr) 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
EP0748220A4 (en) 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
US6124211A (en) 1994-06-14 2000-09-26 Fsi International, Inc. Cleaning method
JPH089997A (ja) 1994-06-28 1996-01-16 Shimadzu Corp 核酸合成法およびそれに用いる試薬キット
WO1996004248A1 (fr) 1994-07-29 1996-02-15 Suntory Limited Derives d'imidazolidine et son utilisation
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
DE19540027A1 (de) 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
FR2741346B1 (fr) 1995-11-16 1997-12-19 Roussel Uclaf Nouveau procede de preparation de derives phenylimidazolidine
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
TW418195B (en) 1995-11-28 2001-01-11 American Home Prod 2-thioxo-imidazolidin-4-one derivatives
CA2238812A1 (en) 1995-11-28 1997-06-05 Theodore Sylvester Sulkowski 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives
US5554607A (en) 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
JP3697320B2 (ja) 1996-06-20 2005-09-21 株式会社日立製作所 光ファイバセンサ
WO1998008533A1 (en) 1996-08-30 1998-03-05 Peptech Limited Sustained peptide-release formulation
US5726061A (en) 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US7053263B2 (en) 1996-10-15 2006-05-30 The Regents Of The University Of California Mouse models of human prostate cancer progression
HUP0001957A3 (en) 1997-02-03 2000-12-28 Dow Agrosciences Llc 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamides with carboxylic acid derivatives on the pyridine ring as fungicides, intermediates, preparation and use thereof
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6506607B1 (en) 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
EP1087770A4 (en) 1998-06-15 2001-11-14 Merck & Co Inc INHIBITORS OF PRENYL PROTEIN TRANSFERASE
JP3390744B2 (ja) 1998-09-22 2003-03-31 山之内製薬株式会社 シアノフェニル誘導体
EP0989122B1 (de) 1998-09-22 2003-05-21 Degussa AG Verfahren zur Herstellung von Imidazolidin-2,4-dionen
AU1308400A (en) 1998-10-30 2000-05-22 G.D. Searle & Co. Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
AU2847200A (en) 1999-01-27 2000-08-18 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
WO2001007048A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6479063B2 (en) 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US6570025B1 (en) 2000-05-31 2003-05-27 Mitsui Chemicals, Inc. Sulfur compound and use thereof
CA2411671C (en) 2000-05-31 2007-06-05 Tanabe Seiyaku Co., Ltd Inhibitors of alpha l beta 2 mediated cell adhesion
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002053155A1 (en) 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
US6710037B2 (en) 2001-05-01 2004-03-23 Schering Corporation Method of treating androgen-dependent disorders
MXPA04002993A (es) 2001-10-01 2004-07-15 Bristol Myers Squibb Co Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios.
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
GB0200283D0 (en) 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
DE10218963A1 (de) 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US20060127902A1 (en) 2002-08-15 2006-06-15 Genzyme Corporation Brain endothelial cell expression patterns
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
FR2845385B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2845384B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
US20040106681A1 (en) 2002-10-03 2004-06-03 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
AU2003279442A1 (en) 2002-10-04 2004-04-23 Laboratoires Fournier S.A. 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2004252175A (ja) 2003-02-20 2004-09-09 Kyocera Mita Corp 現像装置、画像形成装置および現像剤の回収方法
BRPI0411255A (pt) 2003-06-12 2006-08-01 Novo Nordisk As composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
WO2004111012A1 (ja) 2003-06-12 2004-12-23 Chugai Seiyaku Kabushiki Kaisha イミダゾリジン誘導体
PL1632477T3 (pl) 2003-06-12 2017-07-31 Astellas Pharma Inc. Pochodna benzamidu lub jej sól
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
EP1709152A4 (en) 2003-12-15 2007-11-07 Univ California MOLECULAR SIGNATURE OF PTEN TUMOR SUPPRESSOR
US8034548B2 (en) 2003-12-19 2011-10-11 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
CN1960725A (zh) 2004-03-15 2007-05-09 Ptc医疗公司 用于抑制血管发生的四环咔啉衍生物
EP1621536A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
TW200612920A (en) 2004-08-03 2006-05-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivatives
KR20070106969A (ko) 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
AU2005281797B2 (en) 2004-09-10 2011-07-07 Jagotec Ag Tablets with site and time-controlled gastrointestinal release of active ingredient
JP2006265244A (ja) 2005-03-23 2006-10-05 Pfizer Prod Inc Ｃｔｌａ４抗体とホルモン治療を用いた前立腺癌の治療
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
ATE541571T1 (de) 2005-05-13 2012-02-15 Univ California Diarylhydantoin-verbindung
FR2889189A1 (fr) 2005-07-28 2007-02-02 Cerep Sa Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CN101032486B (zh) 2006-03-08 2011-05-11 张宏 逆转唑类药物抗真菌活性多药耐药性的药用植物增效剂
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
PL3412290T3 (pl) 2006-03-27 2021-09-06 The Regents Of The University Of California Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
MX2008012492A (es) 2006-03-29 2008-12-12 Univ California Compuestos de diariltiohidantoina.
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP2425874A3 (en) 2006-08-25 2013-05-15 Cougar Biotechnology, Inc. Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
EP2061561B1 (en) 2006-08-25 2013-07-10 Cougar Biotechnology, Inc. Compositions for treating cancer
EP1905439A1 (en) 2006-09-24 2008-04-02 GPC Biotech AG Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
JP4993996B2 (ja) 2006-10-20 2012-08-08 フクダ電子株式会社 輸液ポンプモニタリング装置
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
TWI557111B (zh) 2007-10-26 2016-11-11 加州大學董事會 二芳基乙內醯脲類化合物
US20100267682A1 (en) 2007-11-09 2010-10-21 Novartis Ag Corticosteroids to treat epothilone or epothilone derivative induced diarrhea
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
US20140187641A1 (en) * 2012-08-23 2014-07-03 Gtx Estrogen receptor ligands and methods of use thereof
SG173837A1 (en) 2009-02-24 2011-09-29 Medivation Prostate Therapeutics Inc Specific diarylhydantoin and diarylthiohydantoin compounds
EP2424537B1 (en) * 2009-04-29 2015-07-08 Bayer Intellectual Property GmbH Substituted imidazoquinoxalines
HUE037389T2 (hu) 2010-02-16 2018-08-28 Aragon Pharmaceuticals Inc Androgén receptor modulátorok és alkalmazásaik
SI3329775T1 (sl) 2010-02-24 2021-09-30 Medivation Prostate Therapeutics Llc Procesi za sintezo spojin diariltiohidantoina in diarilhidantoina
WO2012018948A2 (en) * 2010-08-04 2012-02-09 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
EP2606130B1 (en) * 2010-08-16 2019-03-13 Duke University Camkk-beta as a marker in prostate cancer
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2012142208A1 (en) 2011-04-13 2012-10-18 The Trustees Of The University Of Pennsylvania Bifunctional akr1c3 inhibitors/androgen receptor modulators and methods of use thereof
WO2012145330A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
CA2836277A1 (en) * 2011-05-17 2012-11-22 Takeda Pharmaceutical Company Limited Pharmaceutical compositions and methods for treating cancer
KR101923250B1 (ko) 2011-07-29 2018-11-28 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 유방암의 치료
ES2613098T3 (es) * 2011-08-19 2017-05-22 British Columbia Cancer Agency Branch Compuestos de éter de bisfenol fluorado y métodos para su uso
US20130079241A1 (en) * 2011-09-15 2013-03-28 Jianhua Luo Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse
WO2013079964A1 (en) * 2011-11-30 2013-06-06 Astrazeneca Ab Combination treatment of cancer
EP2817019A4 (en) 2012-02-24 2016-04-06 Univ Chicago METHODS AND COMPOSITIONS ASSOCIATED WITH GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROSTATE CANCER
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
FR2989357B1 (fr) 2012-04-12 2016-02-05 Allia Conditionnement unique pour un ensemble sanitaire comprenant une cuvette de wc suspendu et un bati-support associe
PE20200725A1 (es) 2012-06-07 2020-07-21 Aragon Pharmaceuticals Inc Formas cristalinas del modulador receptor de androgeno: 4-[7-(6-ciano-5-trifluorometilpiridin-3-il)-8-oxo-6-tioxo-5,7-diazaespiro[3,4]oct-5-il]-2-fluoro-n-metilbenzamida) (apalutamida)
SI3725778T1 (sl) 2012-09-11 2022-02-28 Medivation Prostate Therapeutics Llc Formulacije enzalutamida
EA202190820A1 (ru) 2012-09-26 2021-10-29 Арагон Фармасьютикалз, Инк. Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP2988824B1 (en) 2013-04-23 2018-11-07 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
CN105916501A (zh) 2013-12-06 2016-08-31 豪夫迈·罗氏有限公司 用于治疗局部晚期或转移性雌激素受体阳性乳腺癌的雌激素受体调节剂
DK3226842T3 (da) 2014-12-05 2021-01-25 Aragon Pharmaceuticals Inc Anticancersammensætninger
MA41107A (fr) 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
MX2017007206A (es) 2014-12-05 2018-01-30 Aragon Pharmaceuticals Inc Composiciones anticancerigenas.
CN104857157A (zh) 2015-05-12 2015-08-26 四川金堂海纳生物医药技术研究所 一种治疗子宫内膜增殖症的汤剂药物及制备方法
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER

Also Published As

Publication number Publication date
AU2020244431A1 (en) 2020-10-29
EA201590650A1 (ru) 2015-07-30
IL237692A0 (en) 2015-05-31
AU2013323861C1 (en) 2024-05-02
SG10201902568YA (en) 2019-04-29
NI201500042A (es) 2015-09-02
PE20150765A1 (es) 2015-05-15
SI3305285T1 (sl) 2021-03-31
LT3305285T (lt) 2020-12-10
ZA201808499B (en) 2022-12-21
KR102210825B1 (ko) 2021-02-01
IL237692B1 (en) 2023-08-01
AU2018206695B2 (en) 2020-07-02
BR112015006705A2 (pt) 2017-07-04
CA2885415C (en) 2021-06-29
EP3777845A1 (en) 2021-02-17
JP7198310B2 (ja) 2022-12-28
US20180318277A1 (en) 2018-11-08
HUE051211T2 (hu) 2021-03-01
IL237692B2 (en) 2024-07-01
UA117663C2 (uk) 2018-09-10
CN104661658A (zh) 2015-05-27
AU2013323861A1 (en) 2015-04-02
US20210000812A1 (en) 2021-01-07
GT201500071A (es) 2015-12-31
PH12015500615A1 (en) 2015-05-11
CN109908114A (zh) 2019-06-21
BR112015006705A8 (pt) 2019-08-27
US20190269668A1 (en) 2019-09-05
ECSP15011764A (es) 2016-01-29
CY1123716T1 (el) 2022-03-24
JP2018150365A (ja) 2018-09-27
JP6527621B2 (ja) 2019-06-05
UA124967C2 (uk) 2021-12-22
CL2015000715A1 (es) 2015-12-11
PH12018502570A1 (en) 2020-12-07
HK1252867A1 (zh) 2019-06-06
CR20150140A (es) 2015-06-11
US20140088129A1 (en) 2014-03-27
DK3305285T3 (da) 2020-10-26
US20180110764A1 (en) 2018-04-26
US9884054B2 (en) 2018-02-06
MY180834A (en) 2020-12-10
EA201890598A2 (ru) 2018-07-31
EA037806B1 (ru) 2021-05-24
US10799489B2 (en) 2020-10-13
IN2015DN02387A (zh) 2015-09-04
PH12015500615B1 (en) 2015-05-11
EA201890598A3 (ru) 2019-03-29
CN109999036A (zh) 2019-07-12
KR20220025231A (ko) 2022-03-03
IL304337A (en) 2023-09-01
KR20150070192A (ko) 2015-06-24
USRE49353E1 (en) 2023-01-03
AU2018206695C1 (en) 2020-10-22
JP2015531373A (ja) 2015-11-02
NZ745682A (en) 2019-09-27
SG10201912719TA (en) 2020-02-27
NZ705815A (en) 2018-08-31
US10799488B2 (en) 2020-10-13
KR20210013342A (ko) 2021-02-03
JP6896016B2 (ja) 2021-06-30
MX2019010098A (es) 2019-10-15
WO2014052237A1 (en) 2014-04-03
JP6351597B2 (ja) 2018-07-04
NZ744456A (en) 2019-09-27
CN115737643A (zh) 2023-03-07
US10849888B2 (en) 2020-12-01
IL312316A (en) 2024-06-01
HK1212221A1 (zh) 2016-06-10
PH12018502569A1 (en) 2020-12-07
PT3305285T (pt) 2020-11-24
HRP20201721T1 (hr) 2021-02-19
AU2018206695A1 (en) 2018-08-02
EA202190820A1 (ru) 2021-10-29
MX371020B (es) 2020-01-13
JP2019163288A (ja) 2019-09-26
RS60976B1 (sr) 2020-11-30
AU2013323861B2 (en) 2018-04-19
EP3305285A1 (en) 2018-04-11
EP3305285B1 (en) 2020-09-02
CA2885415A1 (en) 2014-04-03
MX2015003909A (es) 2016-01-08
AU2024204555A1 (en) 2024-07-18
US20190269667A1 (en) 2019-09-05
JP2021130718A (ja) 2021-09-09
US10052314B2 (en) 2018-08-21
EA030128B1 (ru) 2018-06-29
EP2900224A1 (en) 2015-08-05
ES2836424T3 (es) 2021-06-25

Similar Documents

Publication Publication Date Title
IL304337A (en) Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
IL288181A (en) Cancer treatment methods
IL263781A (en) Combined treatment of ovarian cancer
EP2903644A4 (en) TREATMENT OF CANCER
ZA201503105B (en) Treatment of prostate cancer with tor kinase inhibitors
GB201217892D0 (en) Treatment of cancer
EP2817011A4 (en) TREATMENT OF CANCER
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201217890D0 (en) Treatment of cancer
HK1200094A1 (zh) 免疫調節劑用於治療癌症的用途
GB201222949D0 (en) Combination Treatment of Cancer
GB201222950D0 (en) Combination treatment of cancer
GB201208296D0 (en) Treatment of cancer